The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.
Rana R. McKay
No relevant relationships to disclose
Gustavo Enrique Rodriguez
Other Remuneration - Pfizer
Xun Lin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ronit Simantov
Employment or Leadership Position - Panacea Pharmaceuticals
Stock Ownership - Pfizer
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer